Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Puretech’s Gelesis flunks the FDA’s key measure of success for weight loss treatments
8 years ago
R&D
Visualize: What would these 11 biotech companies look like without immigrants?
8 years ago
R&D
Biotech Voices
Allergan caps a bad day with news the FDA has kicked back a supplemental application for cariprazine
8 years ago
Pharma
FDA spurns J&J's troubled rheumatoid arthritis drug sirukumab
8 years ago
Pharma
How Enterprise customers can get Endpoints News into their Slack
8 years ago
Publisher's note
AbbVie partners on an Opdivo combo study with Bristol-Myers; Intercept tumbles on FDA warning
8 years ago
News Briefing
GSK vets Witty and Slaoui find new roles in biotech as the great migration continues
8 years ago
Peer Review
Two years on, Allergan’s $1.7B NASH drug still looks weak — at best
8 years ago
R&D
OrbiMed, RA Capital back a $26M raise for Realm’s two mid-stage drugs
8 years ago
Financing
Startups
AbbVie’s top execs paint a rosy pic of the mega-blockbuster future looming for Humira and PhIII drugs
8 years ago
R&D
Pharma
House committee wants to know a lot more about the cyberattack that damaged Merck
8 years ago
Pharma
Versartis shares hammered by a PhIII flop as growth hormone flunks key test
8 years ago
R&D
Sanofi, NIH create a three-pronged antibody to target HIV; Akari soars on PhIII plans; Juno plots planned $225M raise
8 years ago
News Briefing
A China biotech unicorn scores big with $150M-plus IPO on Nasdaq, stock rockets up
8 years ago
Financing
China
Nestle plans to ax hundreds of R&D staffers, shutter big dermatology campus
8 years ago
R&D
Pharma
With help from J&J, upstart Provention lands rights to two mid-stage IBD drugs and shoots for PhII
8 years ago
Startups
Pharma
Chris Garabedian's Xontogeny shepherds its first biotech through a $10M startup round
8 years ago
People
Financing
Want to start fixing the gender diversity problem in your biotech company? Put down the silver bullet
8 years ago
R&D
Pharma
After settling with the SEC, biotech VC Steven Burrill now faces up to 30 years for fraud, tax evasion charges
8 years ago
People
FDA's Janet Woodcock: the clinical trials system is 'broken'
8 years ago
Pharma
Arcus scores $305M regional development pact with Taiho; Shire, Shionogi tout PhIII ADHD study
8 years ago
News Briefing
Angry Pfizer accuses J&J of violating antitrust laws in safeguarding a megablockbuster franchise
8 years ago
Pharma
Sanofi's Elias Zerhouni says his R&D group is ready to stand alone — but big M&A and partnerships still loom large
8 years ago
Deals
Lightstone crew adds a $250M Fund II with plans to back biotech startups
8 years ago
Financing
First page
Previous page
1093
1094
1095
1096
1097
1098
1099
Next page
Last page